Vaxcyte, Inc. (PCVX)

Vaxcyte's stock has been influenced by several key events over the past six months. In February 2026, the company reported financial results, advanced its VAX-31 program, and completed an equity offering. In March 2026, positive VAX-31 Phase 1/2 data was published, and enrollment in OPUS-1 and OPUS-2 Phase 3 trials was completed. In April 2026, Wall Street Zen downgraded the stock to "strong sell," while other analysts maintained a "Moderate Buy" consensus, and the company reported quarterly EPS that missed estimates. In May 2026, Q1 2026 financial results were reported, highlighting the completion of enrollment across all three adult Phase 3 OPUS trials, and despite a strong cash position, the stock tumbled due to a widening net loss and increased R&D expenses, though it saw some gains earlier in the month.

There is no explicit information available regarding demand seasonality for Vaxcyte, Inc.'s products and services, as its current focus is on research, development, and clinical trials rather than commercial sales.

Vaxcyte, Inc. is a clinical-stage vaccine innovation company focused on engineering high-fidelity vaccines against serious bacterial infectious diseases, operating within the Healthcare sector and Biotechnology industry. The company uses its XpressCF cell-free protein synthesis platform to develop vaccine candidates, including VAX-31, a 31-valent pneumococcal conjugate vaccine in Phase 3 adult and Phase 2 infant clinical programs; VAX-24, a 24-valent PCV candidate in a Phase 2 infant study; VAX-A1, a novel conjugate vaccine candidate against Group A Streptococcus infections expected to enter Phase 1 in mid-2026; VAX-PG, a novel protein vaccine candidate targeting Porphyromonas gingivalis; VAX-GI, a preclinical vaccine candidate for dysentery and shigellosis; and VAX-XL, a third-generation PCV candidate in early-stage development.

Vaxcyte, Inc. is headquartered in San Carlos, California. The company has expanded its manufacturing capabilities by completing a large-scale manufacturing facility in collaboration with Lonza and has initiated the buildout of a high-volume fill-finish line in North Carolina to establish a U.S. manufacturing presence.

Vaxcyte's brand reputation is generally reflected through analyst sentiment and industry news, typically holding a "Moderate Buy" consensus rating, though a recent downgrade to "strong sell" indicates mixed sentiment. Events affecting the broader vaccine industry can also indirectly influence investor perception.

Institutional investors hold a significant majority of Vaxcyte's shares, with 308 institutional owners holding 148,903,377 shares as of May 7, 2026; major shareholders include Fmr Llc, Janus Henderson Group Plc, and Vanguard Group Inc. Individual shareholders represent a small fraction of ownership, approximately 0.95% as of December 2025, while insider ownership was 0.68% as of August 2025.